U20. In Vivo Experimental Platform
Located at the Valld’Hebron Research Institute (VHIR) in Barcelona, U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. All three sections are included within the Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine. This unit is leadedby Dr. Ibane Abasolo (Head of FVPR) and supervised by the directorof CIBBIM-Nanomedicine, Dr. Simó Schwartz Jr. Its mission is to offer products and services for the preclinical proof-of-concept validation of therapeutic compounds and biomarkers with potential clinical applications. One of the distinguishing features of this unit is that basic preclinical studies including toxicology, histopathology and efficacy treatments are complemented with non-invasive optical imaging technologies. In vivo bioluminescence and fluorescence imaging allows monitoring of living mice longitudinally, offering real time insight into treatment efficacy, whole-body biodistribution and target mechanisms. Although in Spain there are other institutions with similar equipment, this is the only case in which imaging services can be combined with specifically devoted animal models. FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
27 Jul During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC, Jesús Joglar, the Scientific Coordinator[...] 06 Apr On April 1st PhD candidate Patricia Cámara Sánchez defended her doctoral thesis entitled “Targeting of the breast cancer stem cells to improve the treatment of triple negative breast cancer“, where ICTS-Nanbiosis Unit 20 participated in the in vivo assays. The thesis was supervised by Dr. Ibane Abasolo (scientific director of Unit 20 from CIBER-BBN and VHIR). Nanbiosis was also present within the jury, with Dr. Ana Paula Candiota (scientific coordinator of Unit 25 from CIBER-BBN and UAB) acting as secretary. Patricia Cámara graduated as biochemist, did the master’s degree in Translational Biomedical Research from VHIR-UAB. Shortly after, started the PhD, which was aimed[...] 28 Mar NANBIOSIS, U20. In Vivo Experimental Platform, led by Dr. Ibane Ibasolo, has been updated and improved as a result of its participation in the project FICTS1420-20, selected by the MICINN for co-financing by the FEDER Program in ICTS 2014-2020 (Equipment for setting standardized immunotoxicology assays for the U20 -NANBIOSIS I17 Action of the Investment Plan-)[...] 20 Mar Pancreatic ductal adenocarcinoma is a highly devastating orphan disease with poor prognosis even when diagnosed early (The survival rate after 5 years (< 5%) has not changed over the last 30 years, despite tremendous research efforts) The european project NoCanTher, in wich participates NANBIOSIS U20 of (VHIR and CIBER-BBN) is a nanotechnology-based approach aimed to scale-up under GMP conditions and evaluate a nanoformulation for a combined therapy with chemotherapy against this pancreatic cancer. The international clinical study, carried out in the framework of the project is now incorporating the first pacient in Spain with this type of nanotherapy. The clinica[...] 08 Mar Start-ups / SMEs! Are you working on innovative medical products using nanotechnology? This is your call for development and marketing solutions! Last week took place the SAFE-N-MEDTECH Open Call on line info session with the idea to present the open call with a bit more detail. A few presentations and specially a time for questions and answers were organized by Anaïs Le Corber, Network Manager of CEBERG, the council of European Bioregions, partner of the project. The webinar was recorded and it is available here: First of all, Angel del Pozo, Coordinator of the SAFE-N-MEDTECH, gave an insight of t[...] 28 Feb WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives. Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...] 09 Feb The International Day of Women and Girls in Science on February 11 honor women’s significant achievements in science and place a much-needed focus on girls entering Science, Technology, Engineering, and Mathematics (STEM) careers. We want to take this day to congratulate all the women scientists, especially our scientists at NANBIOSIS ICTS. Some of them take an active role in the dissemination of research results and reseach contribution to the society, as Dr. Ibane Abasolo who last week participated in different events to explain her team work in the figth against breast cancer. Ibane Abasolo is the Scientific Coordinator of NANBIOSIS U20 and also[...] 03 Feb Twenty years ago, the 4 February was declared World Cancer Day with the global challenge of cancer would not be forgotten. Since then, huge progress has been made to understand, prevent, diagnose, and treat cancer. NANBIOSIS as an ICTS (Singular Scientific and Technical infrastructures) for biomedical research plays a very important role in the fight against cancer. Dr. Miriam Royo, who leads NANBIOSIS unit 3 of Synthesis of Peptide, explains one of the projects in which the ICTS is involved in relation with cancer therapy. The improvement of solubility and stability of clinically approved chemotherapeutic drugs still represent a big[...]
U20. In Vivo Experimental Platform
Description
Services
Equipments
Active projects
Title
Fundin: Organism
Call: Funding source
Role
ICTS-2017-10-CIBER-2
Acquisition and istallation of infrastrucuture to complemnt Unis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivo Experiment
Ministerio de Economía, Industria y Competitividad (MINECO)
Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt)
Coordinator
GA: 720942
SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry
Unión Europea (Comisión Europea)
H2020-NMBP-2016-2017
Coordinator
SAF2017-90810-REDI
Strategic Promotion and coordinated
management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)
Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017Coordinator
Other projects
Ref
Title
Funding Organism
Unit Role
RTC-2014-2207-1
TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases
MINECO
Participant
Publications
News U20
1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection
Targeting of the breast cancer stem cells to improve the treatment of triple negative breast cancer
New equipment installed in NANBIOSIS U20
The efficacy of nanoparticles combined with chemotherapy against pancreatic cancer
Open Call Focus on Innovative MedTech using Nanotechnology
Fabry Desease in the Rare Disease Day: A New Hope
Women in the fight against breast cancer: Ibane Ibasolo
Multivalent self-assembled platforms for the delivery of chemotherapeutic drugs
